|
Sep 5
|
Ascendis Pharma Reports Second Quarter 2023 Financial Results
|
|
Sep 5
|
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
|
|
Sep 5
|
New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism
|